Related Experiment Video
Updated: Jul 4, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Three Rounds of Stability-Guided Optimization and Systematical Evaluation of Oncolytic Peptide LTX-315
Xing-Yan Fu1,2, Hao Yin1,2, Xi-Tong Chen1
1School of Pharmacy, Qingdao University Medical College, Qingdao University, #1 Ningde Road, Qingdao 266073, China.
Abstract:
Oncolytic peptides represent promising novel candidates for anticancer treatments. In our efforts to develop oncolytic peptides possessing both high protease stability and durable anticancer efficiency, three rounds of optimization were conducted on the first-in-class oncolytic peptide LTX-315. The robust synthetic method, in vitro and in vivo anticancer activity, and anticancer mechanism were investigated. The D-type peptides represented by FXY-12 possessed significantly improved proteolytic stability and sustained anticancer efficiency. Strikingly, the novel hybrid peptide FXY-30, containing one FXY-12 and two camptothecin moieties, exhibited the most potent in vitro and in vivo anticancer activities. The mechanism explorations indicated that FXY-30 exhibited rapid membranolytic effects and induced severe DNA double-strand breaks to trigger cell apoptosis. Collectively, this study not only established robust strategies to improve the stability and anticancer potential of oncolytic peptides but also provided valuable references for the future development of D-type peptides-based hybrid anticancer chemotherapeutics.
Insights
Researchers optimized oncolytic peptides for cancer treatment, developing D-type peptides like FXY-12 for stability and a hybrid peptide FXY-30 with camptothecin for potent anticancer activity.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Oncolytic peptides are emerging as potent anticancer agents.
- Improving protease stability and sustained efficacy are key challenges in oncolytic peptide development.
- LTX-315 is a first-in-class oncolytic peptide that served as a basis for optimization.
Purpose of the Study:
- To enhance the stability and anticancer efficiency of oncolytic peptides through optimization.
- To investigate the synthesis, activity, and mechanisms of novel peptide derivatives.
- To develop improved peptide-based chemotherapeutics.
Main Methods:
- Iterative optimization of the oncolytic peptide LTX-315 over three rounds.
- Synthesis and characterization of D-type peptides (e.g., FXY-12) and hybrid peptides (e.g., FXY-30).
- In vitro and in vivo evaluation of anticancer activity and mechanistic studies.
Main Results:
- D-type peptides, such as FXY-12, demonstrated significantly enhanced proteolytic stability and sustained anticancer effects.
- The novel hybrid peptide FXY-30, incorporating FXY-12 and camptothecin, exhibited superior in vitro and in vivo anticancer potency.
- FXY-30 induced rapid membranolysis and DNA double-strand breaks, leading to apoptosis.
Conclusions:
- Robust strategies were established for improving oncolytic peptide stability and therapeutic potential.
- D-type peptides offer enhanced stability and sustained anticancer efficiency.
- Hybrid peptides like FXY-30 represent a promising new class of anticancer chemotherapeutics with dual mechanisms of action.
More Related Videos
03:59Production and Optimization of LTE, a Leishmania tarentolae Derived Cell-Free Protein Expression System for Recombinant Protein Production
Published on: November 8, 2024
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
